Sim&Cure

🌟 Behind every seamless Sim&Size experience is a dedicated team committed to client success. In our latest interview, Antoni Neves, the leader of our training & education team, shares how we ensure clients fully leverage the capabilities of Sim&Size 2.0. From smooth installations to personalized training and clinical support, our approach is designed to provide an exceptional experience at every step. “We’re with our clients throughout the entire product life cycle, ensuring they can maximize the impact of Sim&Size 2.0 on their practice.” As we gear up for the U.S. launch of Sim&Size 2.0, we remain focused on delivering unparalleled support to every user. 🎥 Watch the full interview to see how we’re redefining customer support in healthcare innovation: https://lnkd.in/dP5npFMs #SimAndSize2.0 #CustomerSupport #HealthcareInnovation #UserExperience

🌍 Join us in shaping the future of aneurysm treatment! 🌍 At Sim&Cure, we are on a mission to make aneurysm treatment safer, more precise, and globally standardized. Our solution is already trusted by hundreds of hospitals worldwide, and now, we’re taking the next big step. We’re opening our doors to investors like YOU through a crowdfunding campaign with Tudigo, allowing everyone to be part of our journey. 💡 Why invest in Sim&Cure? ✅ A rapidly growing MedTech company with proven success ✅ A solid business model with SaaS solutions already deployed in 45+ countries ✅ A strong vision: to expand, innovate, and save more lives 💰 Want to be part of this revolution? Sign up now to get early access! 👉 https://lnkd.in/d_mjpsCy #InvestInHealthcare #MedTechRevolution #Crowdfunding #HealthInnovation

Therapeutic planning isn’t just about optimizing treatment quality—it’s also key to improving stock management, overall treatment efficiency, and cathlab organization. Thank you, Dr. Răzvan Alexandru Radu, for sharing how Sim&Size has transformed practices at the University Emergency Hospital in Bucharest. By enhancing preplanning and optimizing resources, clinicians have been able to treat more patients efficiently while minimizing material wastage. We’re proud to support medical teams in achieving these outstanding results! 👉 Learn more about Sim&Size and its impact: https://lnkd.in/dfCwdUkm #SimAndSize2.0 #EndovascularCare #HealthcareInnovation #PatientOutcomes #ExpertTestimonial

🚀 Something BIG is coming… and YOU can be part of it first! 🚀 Every year, thousands of lives are impacted by cerebral aneurysms, yet the path to safer, standardized treatments remains a challenge. At Sim&Cure, we have spent the past decade developing cutting-edge digital solutions to optimize aneurysm treatment. Our technology is already helping 400+ hospitals worldwide and benefiting over 30,000 patients. But we’re just getting started. For the first time, we are opening our doors to investors through a crowdfunding campaign with Tudigo. And here’s the exciting part: early investors will get exclusive advantages! 💡 💰 Be among the first to invest and secure priority access to this opportunity. 📢 Don’t miss out on this early bird opportunity! Register now to stay informed about the campaign launch: 👉 https://lnkd.in/d_mjpsCy #MedTech #Innovation #Crowdfunding #HealthcareTransformation #EarlyBirdInvestment

Sim&Cure is featured in the 2025 mapping of French AI startups conducted by France Digitale with the support of Sopra Steria Ventures. A mapping that shines a spotlight on 751 startups putting AI at the heart of their business to change the world with their French touch 🇫🇷 Click here to explore the complete mapping (in French) 👉 https://lnkd.in/gBvSJkhK #MappingIA

Spruce Index - An Indicator of Heterogeneous Deformation In the retrospective study on 81 aneurysms treated with Woven EndoBridge (WEB), the Spruce Index — a unique measure of heterogeneity in device deformation — emerged as a significant predictive factor of aneurysm recurrence during follow-up. The study showed that 97% of patients with a Spruce Index < 0.14 achieved adequate occlusion at follow-up. These findings suggest that a more uniform deformation is potentially associated with a reduced risk of recanalization. With Sim&Size, clinicians can assess and adjust deployment parameters for a seamless fit. Key Data Highlights: - Mean Spruce Index: 0.16 (adequate occlusion group) vs. 0.20 (inadequate occlusion group), p = 0.005 - Optimal Spruce Index cut-off value for achieving adequate occlusion: ≤ 0.14 👉 Check full publication here: https://lnkd.in/dZC-A5SS #Clinicaldata #Innovation #Healthcare

Compression - A Potential Predictor of treatment Success Compression matters, too. Maximum compression of the Woven EndoBridge (WEB) device plays a potential role in aneurysm occlusion. In this retrospective study, reaching a maximum compression > 15.1% was associated with 89% chance of achieving adequate occlusion at follow-up. Sim&Size provides an overall visualisation of the device compression, with local compression evaluation, offering unparalleled insight for optimizing device selection. Make every percentage count when choosing your device. Key Data Highlights: - Mean Maximal compression: 13.4% (inadequate occlusion group) vs. 20.7% (adequate occlusion group), P = 0.009. - Optimal maximal compression cut-off value for achieving adequate occlusion: 15.1% 👉 Check full publication here: https://lnkd.in/dZC-A5SS Federico Cagnazzo Alexis Atallah M.D., MSc Vincent Costalat Amandine René #Clinicaldata #Innovation #Healthcare

🏥Clinical validation is at the core of developing effective medical solutions. In this interview, Amandine and Alexis from our clinical and medical affairs team share their roles in ensuring that Sim&Size™ 2.0 meets the highest clinical standards. They discuss the crucial role of clinical validation in shaping the product, the collaboration across teams to ensure it truly meets the needs of clinicians, and the clinical impact this version is expected to have in endovascular care. 🎥 Watch the full interview to learn how clinical validation and collaboration drive innovation in Sim&Size™ 2.0. https://lnkd.in/d9Nc8Z3M Amandine René Alexis Atallah M.D., MSc #SimAndSize2.0 #clinicalvalidation #medicalaffairs #healthcareinnovation #endovascularcare

In a recent webinar, Dr. Federico Cagnazzo presented groundbreaking results from his retrospective study conducted in Montpellier, in collaboration with our team. Highlighting the impact of numerical simulation in aneurysm treatment, Dr. Cagnazzo shared: "These results are new and probably important for the neurovascular community, as they show the utility of simulation software in providing insights you cannot measure manually. They also open the door to predicting patient outcomes, such as angiographic occlusion." Thank you, Dr. Federico Cagnazzo, for driving innovation and pushing the boundaries of how technology can elevate therapeutic planning for brain aneurysm treatments. 👉 Explore the full insights here: https://lnkd.in/dfCwdUkm 👉 Check full publication here: https://lnkd.in/dZC-A5SS #SimAndSize2.0 #HealthcareInnovation #EndovascularCare #NumericalSimulation #ExpertTestimonial #BrainAneurysmCare

🌟 Hello from ABC WIN 2025 in Val d’Isère! ❄️ Did you know that Val d’Isère is not just a world-renowned ski resort but also rich in history, dating back to the 17th century? This stunning alpine town, surrounded by breathtaking peaks, is the perfect setting for groundbreaking discussions on the future of interventional neuroradiology. We’re delighted to be part of ABC WIN 2025, where we’re engaging with experts from around the world and sharing insights to advance patient care. 📆 To schedule a business meeting with our team on site, connect with: Mathieu Sanchez Christophe Chnafa, Ph.D. Frantz ARMAND If you’re not attending but want to learn more about our latest innovations, feel free to contact us here: https://lnkd.in/e3ts_gV4 Our team is ready to assist you! #ABCWIN2025 #SimAndCure #Innovation #ValdIsère #Neuroradiology